Emerging pharmacological therapies in fragile X syndrome and autism

Area of Science:

• Neuroscience
• Genetics
• Pharmacology

Background:

• Autism spectrum disorder (ASD) is a prevalent neurodevelopmental condition with significant unmet medical needs.
• Nonsyndromic ASD lacks defined molecular pathogenesis, complicating targeted treatment development.
• Syndromic ASD research, particularly fragile X syndrome (FXS), provides valuable insights into potential mechanisms.

Purpose of the Study:

• To compare recent advancements in therapeutics development for ASD with those for fragile X syndrome (FXS).
• To leverage lessons from FXS treatment development to inform future trials in nonsyndromic ASD.
• To identify potential molecular targets for addressing core symptoms of ASD.

Main Methods:

• Review of current research on ASD and FXS pathophysiology.
• Analysis of novel therapeutic candidates for ASD, including oxytocin, vasopressin, and cannabinoids.
• Examination of targeted drug development strategies for FXS, focusing on specific molecular targets like mGluR5 and GABAB receptors.

Main Results:

• Drug development for core ASD symptoms faces challenges in identifying specific molecular targets.
• FXS, a monogenic form of ASD, has a well-defined pathophysiology, enabling focused therapeutic development.
• Targeted approaches for FXS, such as targeting metabotropic glutamate receptor 5, show promise.

Conclusions:

• Understanding FXS pathophysiology and therapeutic strategies can guide the development of treatments for nonsyndromic ASD.
• Future ASD therapeutic trials can benefit from the design and lessons learned from FXS drug development.
• Addressing the unmet medical need in ASD requires continued research into its complex molecular underpinnings and targeted therapeutic interventions.